Philip Morris Intl Q2FY26 Results: Adjusted EPS up 15% to $2.20
- Adjusted diluted EPS rose 15% in dollar terms to $2.20, driven by 14% currency-neutral growth
- Organic net revenue grew 7.6%, exceeding $11 billion for the first time in a quarter
- International smoke-free volumes saw high single-digit growth, with VEEV shipments up 55%
- Full-year guidance maintained despite H1 outperformance, due to planned H2 U.S. investment increases

*this image is generated using AI for illustrative purposes only.
Philip Morris International (NYSE: PM) reported a strong second quarter of fiscal year 2026, with adjusted diluted earnings per share rising 15% in dollar terms to $2.20. The company achieved organic net revenue growth of 7.6%, pushing quarterly net revenues past the $11 billion mark for the first time.
This performance was driven by robust international smoke-free product volumes and favorable combustible dynamics, despite strategic decisions to increase U.S. investments in the second half. The company maintained its full-year guidance, citing the need to support ZYN brand equity and portfolio expansion in the United States.
Financial Performance Highlights
The quarter showcased broad-based strength across key metrics. Organic operating income increased close to 11%, while currency-neutral adjusted diluted EPS grew 14%. In dollar terms, the EPS increase reached 15%, aided by a favorable currency impact of $0.03 primarily due to unrealized transactional effects from deferred tax liabilities associated with a weaker Russian ruble.
| Metric | Q2FY26 Performance | Growth (Organic/Currency-Neutral) |
|---|---|---|
| Net Revenue | >$11 billion | +7.6% |
| Operating Income | $4.8 billion | ~+11% |
| Adjusted Diluted EPS | $2.20 | +14% (CN) / +15% (USD) |
| Total Shipment Volume | N/A | +2.5% |
Smoke-Free Product Momentum
International smoke-free products continued to drive growth, with high single-digit volume growth and double-digit top-line expansion. IQOS adjusted in-market sales volume increased by 5%, excluding transitory headwinds from excise increases in Japan and flavor bans in Poland. Excluding these markets, IQOS growth remained in double digits.
VEEV shipments surged 55% in Q2, with Romania, Greece, and Germany as primary drivers. ZYN shipments in the U.S. increased 2% to 2.9 billion pouches, reflecting stable to slightly growing offtake volumes. The company plans to accelerate U.S. investment in H2 to support ZYN's portfolio expansion, including new variants like ZYN Ultra, and to prepare for the potential launch of IQOS ILUMA.
Combustible Business Resilience
The combustible business outperformed expectations, with shipment volumes increasing 1.1% ahead of forecast. This growth was supported by strong pricing power, with a pricing variance of nearly 10% in Q2, and stable category share at 25.3%. Marlboro maintained its record-high share of 11%. International combustible gross profit grew 8% organically in the quarter.
However, geographic mix remained unfavorable as volume growth skewed toward markets with lower per-unit revenues, such as Indonesia, Turkey, and Egypt, where smoke-free products are banned or limited.
What the Numbers Show
A divergence exists between the reported EPS beat and the underlying operational drivers. While adjusted diluted EPS grew 15% in dollar terms, approximately one-third of the outperformance compared to prior forecasts was attributable to a favorable currency impact linked to unrealized tax effects from the Russian ruble. The remaining two-thirds reflected operational strengths, specifically SG&A phasing where commercial investments shifted to Q3, and stronger-than-expected combustible performance. This suggests that while the core business is robust, a portion of the immediate earnings boost is non-operational and potentially transient.
Guidance and Outlook
Philip Morris Intl maintained its full-year guidance for organic net revenue growth of 5-7% and organic operating income growth of 7-9%. The company now forecasts total shipment volume to be stable to slightly positive for the full year, as high single-digit smoke-free growth offsets cigarette volume declines revised to 2-3%. Adjusted diluted EPS guidance remains at $8.26-$8.41, including an expected currency tailwind of around $0.15.
How will the accelerated U.S. investments in ZYN brand equity and portfolio expansion impact operating margins in the second half of fiscal year 2026?
What are the potential regulatory implications for Philip Morris if the FDA approves the launch of IQOS ILUMA in the United States?
To what extent might the transient currency tailwinds from the Russian ruble reverse in subsequent quarters, affecting reported EPS growth?

































